english

[Ile161]MAGE – A2 (157-166)

[Ile161]MAGE-A2 (157-166) is a modified synthetic peptide analog derived from the melanoma-associated antigen A2 (MAGE-A2). Designed with an isoleucine substitution at position 161, this high-purity epitope enhances stability and HLA binding affinity. It is essential for cancer immunotherapy research, specifically in studying T-cell responses, vaccine development, and targeted immunological assays against MAGE-A2-expressing tumors.

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	[Ile161]MAGE-A2 (157-166), human
CAS NO.	/
Appearance	White to off-white lyophilized powder
Molecular Formula	C59H91N11O15
Molecular Weight	1194.45g/mol
Purity (RP-HPLC)	≥ 95.0%
Solubility	Soluble in water, 0.1 M acetic acid, or DMSO at ≥ 1 mg/mL concentration
Endotoxin	< 1.0 EU/mg
Biological Activity	Recognized by HLA-A2-restricted cytotoxic T lymphocytes (CTLs); induces IFN-γ secretion from antigen-specific T cells; exhibits comparable immunogenicity to native MAGE-A2 (157-166) peptide.
Storage Conditions	Long-term storage at -20°C to -80°C; avoid repeated freeze-thaw cycles.
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

This peptide functions as an optimized HLA class I-restricted epitope, preferentially presented by HLA-A*02:01 molecules. The Ile161 substitution strengthens peptide-MHC complex stability, leading to more efficient activation of cytotoxic T-lymphocytes (CTLs). These activated CTLs specifically recognize and lyse tumor cells expressing the MAGE-A2 antigen, providing a targeted model for investigating adaptive antitumor immunity.

2.PRODUCT INDICATIONS

This product is indicated for research applications in oncology and immunology, including in vitro T-cell stimulation, immune monitoring assays, cancer vaccine design, and preclinical evaluation of adoptive cell therapies. It is also used for epitope optimization studies and as a reference standard in diagnostic development for cancers such as melanoma, lung, and head and neck carcinomas.

3.CLINICAL EFFICACY OF PRODUCT

Although intended for research, preclinical data indicate that modified MAGE-A2 epitopes like [Ile161]MAGE-A2 (157-166) can elicit stronger and more persistent CTL responses compared to wild-type sequences. This enhanced immunogenicity supports its role in improving the efficacy of peptide-based vaccines and T-cell therapies currently under investigation in clinical trials for solid tumors.

4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.